Theravance-GSK's COPD drug wins support of FDA panel

04/18/2013 | Reuters · Bloomberg Businessweek

A panel of FDA advisers endorsed the approval of GlaxoSmithKline and Theravance's Breo Ellipta as a treatment for chronic obstructive pulmonary disease. The once-daily inhaled treatment, a combination of fluticasone furoate and vilanterol, would compete with GSK's Advair and AstraZeneca's Symbicort. The FDA could issue a decision by May 12.

View Full Article in:

Reuters · Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Claims Director
PacificSource
Springfield, OR
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA